Assessment of sarcopenic state in liver diseases and treatment efficacy by carnitine supplementation

Assessment of sarcopenic state in liver diseases and treatment efficacy by carnitine supplementation - Assessment of sarcopenic state and treatment efficacy in liver diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030589

Enrollment

Registered

2018-03-01

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcopenia in liver diseases

Interventions

L-cartinFF 1500mg/day supplementation for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who meets the criteria of sarcopenia in liver diseases by the Japan society of hepatology

Exclusion criteria

Exclusion criteria: 1)The patient who has already taken carnitine 2)The patient equivalent to stageIV in hepatocellular carcinoma 3)The pregnant woman 4)The breast-feeding women 5)The patient who received other study medicine or the clinical experimental medicine within three months before dosage start of the study 6)In addition, the patient whom principal investigators judged to be inappropriate as a study subject

Design outcomes

Primary

Measure	Time frame
Prevalence of sarcopenia in liver diseases, Treatment efficacy by carnitine supplementation(after 3months, after 6months)	—

Secondary

Measure	Time frame
serum ammonia neuropsychiatric function test	—

Countries

Japan

Contacts

Public ContactTakuya Adachi

Okayama university hospital Gastroenterology

adataku719@yahoo.co.jp086-235-7219

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026